| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | 0.0075 | 0.9 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | BRD9876:MK-1775 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.9 |
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | 0.0024 | 0.9 |